Loading
Every dated change on the records linked to Intrahepatic cholangiocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
3-year overall survival 77.
Confirmed ORR by independent central review 41.
OS 12.
A milestone in how this cancer is treated.
Previously treated FGFR2-fusion/rearranged intrahepatic cholangiocarcinoma (accelerated)
ORR 42%; PFS 9.
OS HR 0.
A milestone in how this cancer is treated.